Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Global Ventricular Tachycardia Pipeline Review, H2 2018 - Therapeutic Analysis of 6 Companies & Drug Profiles - ResearchAndMarkets.com

Research and Markets
Posted on: 19 Oct 18

The "Ventricular Tachycardia - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

Ventricular Tachycardia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Ventricular Tachycardia (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ventricular Tachycardia (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Ventricular Tachycardia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes; the molecules developed by Companies in Phase III, Phase II, IND/CTA Filed and Preclinical stages are 2, 2, 1 and 4 respectively.

Ventricular Tachycardia (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Report Coverage
  3. Ventricular Tachycardia - Overview
  4. Ventricular Tachycardia - Therapeutics Development
  5. Pipeline Overview
  6. Pipeline by Companies
  7. Products under Development by Companies
  8. Ventricular Tachycardia - Therapeutics Assessment
  9. Assessment by Target
  10. Assessment by Mechanism of Action
  11. Assessment by Route of Administration
  12. Assessment by Molecule Type
  13. Ventricular Tachycardia - Companies Involved in Therapeutics Development
  • Audentes Therapeutics Inc
  • Gilead Sciences Inc
  • HUYA Bioscience International LLC
  • InCarda Therapeutics Inc
  • Milestone Pharmaceuticals Inc
  • Ono Pharmaceutical Co Ltd

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/34hts4/global?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181017005656/en/

Business Wire
www.businesswire.com

Last updated on: 19/10/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.